ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Even when antibiotics pummel a bacterial infection, a small population of the pathogen hunkers down and hibernates, thereby avoiding total destruction. After some time, these so-called persistent bacteria flare up and are responsible for the chronic infections found in patients, such as those with implanted medical devices. Researchers led by Kim Lewis of Northeastern University report that molecules with acyldepsipeptide architectures can kill persistent pathogens such as Staphylococcus aureus when used in combination with rifampicin, ciprofloxacin, or other common antibiotics (Nature 2013, DOI: 10.1038/nature12790). Those drugs typically kill growing cells by targeting the cells’ replication biomachinery. But hibernating bacteria aren’t replicating and thus escape. Lewis’s team found that an acyldepsipeptide molecule, ADEP 4, can activate cellular machinery called proteases, which chop up proteins. ADEP 4 causes proteases to open wide and break down proteins unselectively, causing persistent bacteria to digest their own cells. Bacteria could easily evolve resistance to ADEP 4 if it were used alone. But as the team shows, the pair of antibiotics clears infections—including persistent bacteria—in mice.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter